Chengdu Yunhai Tetrahedron Biotech Co., Ltd. is an innovative framework nucleic acid technology platform company headquartered in the Jinniu District of Chengdu. The company is primarily composed of Professor Yunfeng Lin’s team from The State Key Laboratory of Oral Disease (SKLOD). Based on the team’s invention of the DNA tetrahedron framework nucleic acid drug system, Yunhai has established the Yunhai Tetrahedral Framework Nucleic Acid General Technology Platform. The company manages and operates nucleic acid tetrahedron-related patents worldwide, engages in independent or collaborative research and development with industry partners, and supports the translation and industrialization of tetrahedral framework nucleic acid technology achievements in the fields of advanced therapeutic medicinal products (ATMP) and medical aesthetic supplies.

Tetrahedral Framework Nucleic Acid Patent Operation Platform

Professor Yunfeng Lin from the West China School of Stomatology, Sichuan University, as the primary inventor, has led his team in a long-term, relentless research effort to develop the tetrahedral framework nucleic acid drug system. This system is recognized as a groundbreaking advancement in the global field of nucleic acid drugs. Yunhai Biotech has systematically incorporated the core patents of Professor Yunfeng Lin’s team into the company and has partnered with "The State Key Laboratory of Oral Disease" to jointly establish an "Engineering Research Center." This collaboration aims to continuously produce patents related to the tetrahedral framework nucleic acid, ensuring comprehensive technological leadership, trend-setting influence, and a rich direction for industrial transformation. Additionally, through methods such as patent licensing, patent equity investment, and patent transfer, Yunhai Biotech shares its cutting-edge research achievements in the tetrahedral framework nucleic acid field with global industry partners, jointly advancing the transformation and commercialization of research outcomes in this domain.

Tetrahedral Framework Nucleic Acid Technology Acceleration Platform

The Yunhai Tetrahedral Framework Nucleic Acid General Technology Platform integrates the theoretical system, technical standards, and production processes of framework nucleic acid technology. This technology system is expected to become a leading source of innovation for global drug delivery systems, potentially revolutionizing existing drugs and treatment methods while guiding the trends in the next generation of modern drugs and drug delivery systems worldwide. Yunhai Biotech's industrialization team possesses extensive engineering management experience and offers efficient technology transfer support and clinical conversion enhancement services. Leveraging its substantial expertise in drug development management, comprehensive regulatory approval processes, and pharmaceutical enterprise management, the team aims to significantly boost the speed, flexibility, and value of framework nucleic acid product development in both nucleic acid drugs and non-drug applications.

Tetrahedral Framework Nucleic Acid Engineering Research Center

The Yunhai Tetrahedral Framework Nucleic Acid Engineering Research Center is staffed by 15 postdoctoral researchers, 32 Ph.D. holders, 49 master's degree holders, and 26 undergraduates. The center conducts concept validation research, pharmacological studies, and pilot-scale industrialization at three main locations: the Concept Verification Center in the Sichuan University-Yunhai Biotech Joint Laboratory (which is supported by The State Key Laboratory of Oral Disease, with a total laboratory area of 15,000 square meters and equipment valued at 320 million RMB), the Yunhai Biotech API Production Base in China’s Dental Valley (covering 1,000 square meters with equipment valued at 20 million RMB), and the Yunhai Biotech Pilot Plant at the Chengdu Frontier Medical Center (spanning 1,100 square meters with equipment worth 35 million RMB). These facilities provide a solid foundation for the research, transformation, and commercialization of tetrahedral framework nucleic acids in innovative drugs, medical aesthetics, and other fields.

Social Responsibility: National Security and Public Health

Nucleic acid drugs are advanced therapy medicinal products (ATMPs) that have attracted global market attention. China entered the biopharmaceutical field relatively late, while other countries established technological barriers through patent strategies. The research on DNA tetrahedral framework nucleic acids has not only overcome these technological barriers but also positioned China as a leader in this field, surpassing the United States and providing a significant advantage for China to capture the global market for the next generation of nucleic acid drugs.

China is facing a serious aging issue, and the industrialization of nucleic acid drugs has a positive impact on the treatment of various chronic and major diseases. Tetrahedral framework nucleic acids have shown superior efficacy in treating chronic diseases such as macular degeneration, diabetes, Alzheimer's disease, osteonecrosis, and depression. For major diseases like malignant tumors, tetrahedral framework nucleic acids offer more safe and effective treatment options.